Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Has Average Target Price of $107.44 According to Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Free Report) has been given a consensus rating of “Hold” by the fourteen analysts that are presently covering the company, Marketbeat reports. Eleven research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $107.44.

Several research firms recently weighed in on LNTH. Truist Financial lowered Lantheus from a “buy” rating to a “hold” rating and decreased their price target for the company from $125.00 to $102.50 in a report on Monday, August 3rd. Mizuho lowered shares of Lantheus from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $115.00 to $109.00 in a research note on Tuesday, October 13th. CJS Securities lowered shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. TD Cowen cut shares of Lantheus from a “buy” rating to a “hold” rating and cut their price objective for the company from $110.00 to $102.50 in a research report on Monday, August 3rd. Finally, B. Riley Financial downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th.

View Our Latest Stock Report on LNTH

Institutional Trading of Lantheus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jupiter Topco LLC purchased a new position in shares of Lantheus during the second quarter valued at approximately $575,628,000. Reinhart Partners LLC. raised its holdings in shares of Lantheus by 2.2% in the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after buying an additional 34,501 shares during the period. Carmignac Gestion raised its holdings in shares of Lantheus by 0.9% in the second quarter. Carmignac Gestion now owns 1,340,100 shares of the medical equipment provider’s stock worth $148,671,000 after buying an additional 12,100 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Lantheus by 440.3% in the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after buying an additional 582,661 shares during the period. Finally, Epoch Investment Partners Inc. lifted its stake in shares of Lantheus by 59.4% during the 1st quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock worth $49,284,000 after acquiring an additional 242,222 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Price Performance

Lantheus stock opened at $100.10 on Monday. The company has a market cap of $6.54 billion, a price-to-earnings ratio of 24.18 and a beta of -0.06. The firm’s fifty day moving average is $100.26 and its 200 day moving average is $90.84. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43. Lantheus has a 52-week low of $50.15 and a 52-week high of $111.86.

Lantheus (NASDAQ:LNTH – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. During the same quarter last year, the business earned $1.57 earnings per share. Lantheus’s quarterly revenue was up 2.7% compared to the same quarter last year. Sell-side analysts forecast that Lantheus will post 4.54 EPS for the current fiscal year.

About Lantheus

(Get Free Report)

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.

Read More

Analyst Recommendations for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.